Trials / Active Not Recruiting
Active Not RecruitingNCT07204236
Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological Conversion
- Status
- Active Not Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to assess the immunogenicity and safety of TVAX-008 injection in antiviral untreated/untreated chronic hepatitis B patients with HBsAg≤20 IU/mL, or HBsAg negative and no seroconversion through an investigator-initiated clinical study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TVAX-008 | TVAX-008 |
Timeline
- Start date
- 2024-01-18
- Primary completion
- 2025-03-01
- Completion
- 2026-03-01
- First posted
- 2025-10-02
- Last updated
- 2025-10-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07204236. Inclusion in this directory is not an endorsement.